open access

Ahead of Print
Research paper
Published online: 2023-01-20
Get Citation

Survivin expression at the mRNA level in tumors and the protein concentration in the serum and peritoneal fluid in patients with serous ovarian tumors

Celina Kruszniewska-Rajs1, Marta Smycz-Kubanska2, Barbara Strzalka-Mrozik1, Jaroslaw Strzelczyk2, Wojciech Szanecki3, Andrzej Witek3, Joanna Gola1, Aleksandra Mielczarek-Palacz2
DOI: 10.5603/GP.a2022.0158
Affiliations
  1. Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec Medical University of Silesia, Katowice, Poland
  2. Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland
  3. Department of Gynecology and Obstetrics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2023-01-20

Abstract

Objectives: Ovarian cancer is one of the gynecological cancers that have the worst prognosis. The expression of the proteins from the IAP family (inhibitor of apoptosis protein), including survivin, is observed in many types of cancer.

The aim of the study was to evaluate survivin at the mRNA level in tumors and the protein concentration in the serum and peritoneal fluid of patients with serous ovarian cancer in order to assess the relationship between the concentration of survivin and the histological subtypes of cancer.

Material and methods: The study group consisted of 55 women, including patients with serous ovarian cancer (n = 30, nine low-grade serous carcinoma LGSC, 21 high-grade serous carcinoma HGSC), serous cysts (n = 10) and the control group (n = 15). The concentration of protein in the peritoneal fluid and serum was assessed using ELISA tests. The expression of survivin gene BIRC5 in the tumors was assessed using the RT-qPCR method.

Results: The data that was obtained indicated that the concentration of survivin was higher in the serum of the women with serous ovarian cancer compared those that had benign tumors (p < 0.05) and the control group (p < 0.001). The survivin concentration was also higher in both the serum and peritoneal fluid in the HGSC group compared to the LGSC group (p < 0.001). The mRNA level was highest in the HGSC group, and there was a statistically significant difference compared to those in the benign tumor group and HGSC group ( p < 0.05).

Conclusions: The observed changes prove that the expression level increases significantly in HGSC in both the protein and mRNA levels. Based on these findings, it can be assumed that assessing this parameter could be a useful additional indicator of the progression and differentiation of this type of cancer. However, this requires further research in a larger group of patients and possibly in other types of ovarian cancer

Abstract

Objectives: Ovarian cancer is one of the gynecological cancers that have the worst prognosis. The expression of the proteins from the IAP family (inhibitor of apoptosis protein), including survivin, is observed in many types of cancer.

The aim of the study was to evaluate survivin at the mRNA level in tumors and the protein concentration in the serum and peritoneal fluid of patients with serous ovarian cancer in order to assess the relationship between the concentration of survivin and the histological subtypes of cancer.

Material and methods: The study group consisted of 55 women, including patients with serous ovarian cancer (n = 30, nine low-grade serous carcinoma LGSC, 21 high-grade serous carcinoma HGSC), serous cysts (n = 10) and the control group (n = 15). The concentration of protein in the peritoneal fluid and serum was assessed using ELISA tests. The expression of survivin gene BIRC5 in the tumors was assessed using the RT-qPCR method.

Results: The data that was obtained indicated that the concentration of survivin was higher in the serum of the women with serous ovarian cancer compared those that had benign tumors (p < 0.05) and the control group (p < 0.001). The survivin concentration was also higher in both the serum and peritoneal fluid in the HGSC group compared to the LGSC group (p < 0.001). The mRNA level was highest in the HGSC group, and there was a statistically significant difference compared to those in the benign tumor group and HGSC group ( p < 0.05).

Conclusions: The observed changes prove that the expression level increases significantly in HGSC in both the protein and mRNA levels. Based on these findings, it can be assumed that assessing this parameter could be a useful additional indicator of the progression and differentiation of this type of cancer. However, this requires further research in a larger group of patients and possibly in other types of ovarian cancer

Get Citation

Keywords

ovarian cancer; survivin; molecular marker; gene expression

About this article
Title

Survivin expression at the mRNA level in tumors and the protein concentration in the serum and peritoneal fluid in patients with serous ovarian tumors

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2023-01-20

Page views

7

Article views/downloads

7

DOI

10.5603/GP.a2022.0158

Keywords

ovarian cancer
survivin
molecular marker
gene expression

Authors

Celina Kruszniewska-Rajs
Marta Smycz-Kubanska
Barbara Strzalka-Mrozik
Jaroslaw Strzelczyk
Wojciech Szanecki
Andrzej Witek
Joanna Gola
Aleksandra Mielczarek-Palacz

References (27)
  1. Momenimovahed Z, Tiznobaik A, Taheri S, et al. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019; 11: 287–299.
  2. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019; 35(2): 151–156.
  3. Kujawa KA, Lisowska KM. [Ovarian cancer--from biology to clinic]. Postepy Hig Med Dosw (Online). 2015; 69: 1275–1290.
  4. Binju M, Amaya-Padilla MA, Wan G, et al. Therapeutic inducers of apoptosis in ovarian cancer. Cancers (Basel). 2019; 11(11).
  5. Chandra A, Pius C, Nabeel M, et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019; 8(16): 7018–7031.
  6. Denel-Bobrowska M, Marczak A. The role of survivin in the diagnosis and therapy of gynaecological cancers. Postepy Hig Med Dosw (Online). 2016; 70(0): 1182–1189.
  7. Nogueira-Ferreira R, Vitorino R, Ferreira-Pinto MJ, et al. Exploring the role of post-translational modifications on protein-protein interactions with survivin. Arch Biochem Biophys. 2013; 538(2): 64–70.
  8. Athanasoula KCh, Gogas H, Polonifi K, et al. Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Lett. 2014; 347(2): 175–182.
  9. Waligórska-Stachura J, Andrusiewicz M, Sawicka-Gutaj N, et al. Evaluation of survivin splice variants in pituitary tumors. Pituitary. 2015; 18(3): 410–416.
  10. Wheatley SP. The functional repertoire of survivin's tails. Cell Cycle. 2015; 14(2): 261–268.
  11. Jaiswal PK, Goel A, Mittal RD. Survivin: A molecular biomarker in cancer. Indian J Med Res. 2015; 141(4): 389–397.
  12. Garg H, Suri P, Gupta JC, et al. Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016; 16: 49.
  13. Shojaei F, Yazdani-Nafchi F, Banitalebi-Dehkordi M, et al. Trace of survivin in cancer. Eur J Cancer Prev. 2019; 28(4): 365–372.
  14. Cao XQ, Lu HS, Zhang L, et al. MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis. Asian Pac J Cancer Prev. 2014; 15(13): 5271–5276.
  15. Zhang Yi, Chen Hx, Zhou Sy, et al. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Mol Cancer. 2015; 14: 56.
  16. Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25(4): 402–408.
  17. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6): 1101–1108.
  18. Cetraro P, Plaza-Diaz J, MacKenzie A, et al. A review of the current impact of inhibitors of apoptosis proteins and their repression in cancer. Cancers (Basel). 2022; 14(7).
  19. Nowak-Markwitz E, Puła B, Szajnik M, et al. [Expression of survivin, SDF-1 and CXCR4 on tumor cells in ovarian cancer]. Ginekol Pol. 2010; 81(9): 674–677.
  20. Plewka D, Jakubiec-Bartnik B, Morek M, et al. Survivin in ovary tumors. Ginekol Pol. 2015; 86(7): 525–530.
  21. Turan G, Usta CS, Usta A, et al. The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables. J Mol Histol. 2014; 45(6): 679–687.
  22. Kanter M, Turan G, Usta C, et al. Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms. J Mol Histol. 2016; 47(2): 145–152.
  23. Kucukgoz Gulec U, Gumurdulu D, Guzel AB, et al. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet. 2014; 289(2): 393–398.
  24. Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, et al. Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma. Tumour Biol. 2015; 36(6): 4157–4165.
  25. No JH, Jeon YT, Kim YB, et al. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer. Gynecol Obstet Invest. 2011; 71(2): 136–140.
  26. Gunaldi M, Isiksacan N, Kocoglu H, et al. The value of serum survivin level in early diagnosis of cancer. J Cancer Res Ther. 2018; 14(3): 570–573.
  27. He X, Yang K, Wang H, et al. Expression and clinical significance of survivin in ovarian cancer: A meta-analysis. PLoS One. 2018; 13(5): e0194463.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl